Alyssa Golden

2.3k total citations · 1 hit paper
44 papers, 1.6k citations indexed

About

Alyssa Golden is a scholar working on Epidemiology, Public Health, Environmental and Occupational Health and Molecular Medicine. According to data from OpenAlex, Alyssa Golden has authored 44 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Epidemiology, 16 papers in Public Health, Environmental and Occupational Health and 13 papers in Molecular Medicine. Recurrent topics in Alyssa Golden's work include Pneumonia and Respiratory Infections (24 papers), Streptococcal Infections and Treatments (16 papers) and Antibiotic Resistance in Bacteria (13 papers). Alyssa Golden is often cited by papers focused on Pneumonia and Respiratory Infections (24 papers), Streptococcal Infections and Treatments (16 papers) and Antibiotic Resistance in Bacteria (13 papers). Alyssa Golden collaborates with scholars based in Canada, United States and Barbados. Alyssa Golden's co-authors include George G. Zhanel, Heather J. Adam, James A. Karlowsky, Andrew Walkty, Philippe Lagacé‐Wiens, Frank Schweizer, Sheryl Zelenitsky, Daryl J. Hoban, Joseph P. Lynch and Michael A. Zhanel and has published in prestigious journals such as Emerging infectious diseases, Journal of Antimicrobial Chemotherapy and Drugs.

In The Last Decade

Alyssa Golden

41 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli

2019 311 citations George G. Zhanel, Alyssa Golden et al. Drugs profile →

Peers

Alyssa Golden

EPIDE

PHARM

AMB

Melanie Baxter Canada

Gauri G. Rao United States

Elizabeth B. Hirsch United States

Thomas Tängdén Sweden

Kim Nichol Canada

Noriel Mariano United States

R. Guidos United States

S. Bouchillon United States

Sofia K. Kasiakou Greece

Michael Kresken Germany

Melanie Baxter Canada

Alyssa Golden

841 ×1.0

679 ×1.1

EPIDE

448 ×0.8

PHARM

337 ×1.2

291 ×1.1

AMB

Citations per year, relative to Alyssa Golden Alyssa Golden (= 1×) peers Melanie Baxter

Countries citing papers authored by Alyssa Golden

Since Specialization

Citations

This map shows the geographic impact of Alyssa Golden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alyssa Golden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alyssa Golden more than expected).

Fields of papers citing papers by Alyssa Golden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alyssa Golden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alyssa Golden. The network helps show where Alyssa Golden may publish in the future.

Co-authorship network of co-authors of Alyssa Golden

This figure shows the co-authorship network connecting the top 25 collaborators of Alyssa Golden. A scholar is included among the top collaborators of Alyssa Golden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alyssa Golden. Alyssa Golden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ximenes, Raphael, Gebremedhin Beedemariam Gebretekle, Eva Wong, et al.. (2025). Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada. Vaccine. 54. 126985–126985. 1 indexed citations

Golden, Alyssa, Gregory J. Tyrrell, Julianne V. Kus, et al.. (2024). Invasive Group A Streptococcus Hypervirulent M1_UK Clone, Canada, 2018–2023. Emerging infectious diseases. 30(11). 2409–2413. 4 indexed citations

Golden, Alyssa, Brigitte Lefebvre, Allison McGeer, et al.. (2024). Invasive pneumococcal disease surveillance in Canada, 2021–2022. Canada Communicable Disease Report. 50(5). 121–134. 11 indexed citations

Tyrrell, Gregory J., et al.. (2024). Group A streptococcal infections in Alberta, Canada 2018–2023. Epidemiology and Infection. 153. e35–e35. 3 indexed citations

Golden, Alyssa, Julianne V. Kus, Allison McGeer, et al.. (2024). Invasive group A streptococcal disease surveillance in Canada, 2021–2022. Canada Communicable Disease Report. 50(5). 135–143. 6 indexed citations

Adam, Heather J., James A. Karlowsky, Melanie Baxter, et al.. (2023). Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011–2020. Journal of Antimicrobial Chemotherapy. 78(Supplement_1). i17–i25. 8 indexed citations

Golden, Alyssa, Brigitte Lefebvre, Geneviève Deceuninck, et al.. (2023). Clonal diversity of Streptococcus pneumoniae serotype 19A collected from children < 5 years old in Québec, Canada, 2016–2021. Vaccine. 41(44). 6612–6618. 1 indexed citations

Alford, Morgan A., James A. Karlowsky, Heather J. Adam, et al.. (2023). Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011–2020. Journal of Antimicrobial Chemotherapy. 78(Supplement_1). i8–i16. 7 indexed citations

Zhanel, George G., Alyssa Golden, Courtney K. Lawrence, et al.. (2022). Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. Drugs. 82(5). 533–557. 27 indexed citations

10.

Golden, Alyssa, Melanie Baxter, James A. Karlowsky, et al.. (2021). Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19. JAC-Antimicrobial Resistance. 4(1). dlab197–dlab197. 18 indexed citations

11.

Golden, Alyssa, James A. Karlowsky, Andrew Walkty, et al.. (2021). Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing Escherichia coli collected from Canadian hospitals: CANWARD 2007–18. Journal of Antimicrobial Chemotherapy. 76(11). 2825–2832. 7 indexed citations

12.

Golden, Alyssa, Heather J. Adam, Melanie Baxter, et al.. (2021). Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007–2018. Vaccine. 39(39). 5474–5483. 7 indexed citations

13.

Walkty, Andrew, James A. Karlowsky, Melanie Baxter, et al.. (2021). In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019. Diagnostic Microbiology and Infectious Disease. 101(1). 115418–115418. 10 indexed citations

14.

Zhanel, George G., Sheryl Zelenitsky, Courtney K. Lawrence, et al.. (2020). Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs. 81(2). 233–256. 37 indexed citations

15.

Zhanel, George G., Alyssa Golden, Sheryl Zelenitsky, et al.. (2019). Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs. 79(3). 271–289. 311 indexed citations breakdown →

16.

Zhanel, George G., Courtney K. Lawrence, Heather J. Adam, et al.. (2017). Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs. 78(1). 65–98. 288 indexed citations

17.

Zhanel, George G., Heather J. Adam, Sheryl Zelenitsky, et al.. (2016). Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. Drugs. 76(5). 567–588. 214 indexed citations

18.

Zhanel, George G., Heather J. Adam, Sheryl Zelenitsky, et al.. (2016). Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs. 76(18). 1737–1757. 37 indexed citations

19.

Golden, Alyssa, Heather J. Adam, & George G. Zhanel. (2016). Invasive Streptococcus pneumoniae in Canada, 2011–2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F. Vaccine. 34(23). 2527–2530. 27 indexed citations

20.

Zhanel, George G., Heather J. Adam, Alyssa Golden, et al.. (2015). Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens. Drugs. 75(3). 253–270. 138 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact